Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$64.74

2.67 (4.30%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55

Ionis Pharmaceuticals management to meet with Piper Jaffray

Meeting to be held in London, England on June 17-18 hosted by Piper Jaffray.

  • 18

    Jun

IONS Ionis Pharmaceuticals
$64.74

2.67 (4.30%)

05/07/19
PIPR
05/07/19
NO CHANGE
Target $142
PIPR
Overweight
Piper more confident in estimates for Alnylam's Onpattro after doctor survey
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $142 price target after surveying 16 physicians treating 490 hereditary transthyretin amyloidosis patients with polyneuropathy. Doctors have a "clear preference" for Alnylam's Onpattro over Onpattro and Ionis Pharmaceuticals' (IONS) Tegsedi, with efficacy, safety, and experience being cited, Tenthoff tells investors in a research note. Roughly two-thirds of existing and new gene silencer patients are prescribed Onpattro, says the analyst. Based on the survey results, the analyst is increasingly confident in his 2019 Onpattro sales estimates of $127M.
05/07/19
MSCO
05/07/19
NO CHANGE
MSCO
Biogen could rise, or fall, 5% based on Zolgensma label, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Novartis' (NVS) gene therapy for the rare disease spinal muscular atrophy, Zolgensma, is expected to be approved by the FDA this month. He also noted that Biogen's (BIIB) Spinraza is currently the only approved drug for SMA and represents 17% of Biogen's estimated 2019 sales. The public data for Novartis' Zolgensma are only in type 1 patients, or infants, said Harrison, who sees three potential scenarios for the drug's label. In the first, which would involve broad approval across the three patient classes of infants, children and adults, Harrison thinks Novartis shares could be up 1-2%, Biogen could fall about 5%, Ionis (IONS), which receives royalties from Biogen, could be down about 10%, and Regenxbio (RGNX), which will receive royalties from Novartis, could be up 10-15% or more. In the second case, where Zolgensma is granted a Type 1 approval with no restriction, Harrison sees Novartis unchanged, Biogen down 1-3%, Ionis falling 3-5% and Regenxbio rising 5%. In the third scenario, where Zolgensma gets a Type 1 approval but with a weight/age restriction, the analyst thinks Novartis would be down 1-2%, Biogen would be up 2-3%, Ionis could rise 5% and Regenxbio could fall 5-10%. Harrison's base case assumption is that Zolgensma will ultimately capture the majority market share in type 1 patients and a "significant portion" of type 2, or pediatric, patients.
05/09/19
PIPR
05/09/19
NO CHANGE
Target $75
PIPR
Neutral
Ionis Pharmaceuticals shares 'more interesting on pullback', says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren kept his Neutral rating and $75 price target on Ionis Pharmaceuticals after its Q1 results with Spinraza royalties and Tegsedi sales seen "in line with expectations". The analyst believes that the company's pipeline is maturing as it gets ready to launch Waylivra in Europe next quarter and also sees its Huntington's OLE continuing to progress. Van Buren contends that Ionis Pharmaceuticals stock is "becoming more interesting" from a long term investment perspective given the recent pullback in price.
05/24/19
PIPR
05/24/19
NO CHANGE
Target $75
PIPR
Neutral
Piper 'incrementally more positive' on Ionis after management meetings
Piper Jaffray analyst Tyler Van Buren says he's "incrementally more positive" on shares of Ionis Pharmaceuticals after hosting meetings with management. The company is in a "healthy and very rare" financial position relative to other mid-cap biotechs with ongoing profitability, $2.3B in cash, and nearly $400M in "durable" annual research and development revenues that offset R&D expenses, Van Buren tells investors in a research note. This provides Ionis valuation support, long-term stability, and allows for value creation on a "step-function basis" as each additional clinical asset becomes de-risked, adds the analyst. Van Buren keeps a Neutral rating on the shares with a $75 price target.

TODAY'S FREE FLY STORIES

XONE

ExOne

$7.38

-0.21 (-2.77%)

, SIEGY

Siemens

$0.00

(0.00%)

05:28
06/25/19
06/25
05:28
06/25/19
05:28
Hot Stocks
ExOne announces partnership with Siemens »

ExOne (XONE) announced a…

XONE

ExOne

$7.38

-0.21 (-2.77%)

SIEGY

Siemens

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPTN

SpartanNash

$10.87

-0.05 (-0.46%)

05:23
06/25/19
06/25
05:23
06/25/19
05:23
Initiation
SpartanNash initiated  »

SpartanNash initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DERM

Dermira

$9.51

-0.405 (-4.08%)

05:23
06/25/19
06/25
05:23
06/25/19
05:23
Hot Stocks
Almirall exercises option with Dermira to license rights to lebrikizumab in EU »

Almirall and Dermira…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGHF

Telenet

$0.00

(0.00%)

05:15
06/25/19
06/25
05:15
06/25/19
05:15
Downgrade
Telenet rating change  »

Telenet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DK

Delek US

$39.13

-0.635 (-1.60%)

05:14
06/25/19
06/25
05:14
06/25/19
05:14
Downgrade
Delek US rating change  »

Delek US downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$11.43

1.44 (14.41%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Downgrade
Caesars rating change  »

Caesars downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jul

GRUB

GrubHub

$72.05

0.91 (1.28%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Upgrade
GrubHub rating change  »

GrubHub upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 09

    Jul

SITE

SiteOne Landscape

$66.97

-0.25 (-0.37%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Upgrade
SiteOne Landscape rating change  »

SiteOne Landscape…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,913.43

3.01 (0.16%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Hot Stocks
Amazon announces 48 hour Prime Day July 15 & 16 »

Amazon said, "This…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 10

    Jul

BHF

Brighthouse Financial

$38.10

-0.01 (-0.03%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Downgrade
Brighthouse Financial rating change  »

Brighthouse Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIF

Tiffany

$91.86

-1.78 (-1.90%)

05:09
06/25/19
06/25
05:09
06/25/19
05:09
Downgrade
Tiffany rating change  »

Tiffany downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTES

Gates Industrial

$10.82

-0.18 (-1.64%)

05:06
06/25/19
06/25
05:06
06/25/19
05:06
Upgrade
Gates Industrial rating change  »

Gates Industrial upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STNG

Scorpio Tankers

$25.90

-0.15 (-0.58%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
Scorpio Tankers management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

SMSEY

Samsonite International

$0.00

(0.00%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
Samsonite International management to meet with CIBC »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

EGBN

Eagle Bancorp

$53.04

-0.45 (-0.84%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
Eagle Bancorp management to meet with Sandler ONeill »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 15

    Aug

  • 11

    Sep

ALG

Alamo Group

$98.92

-0.2 (-0.20%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
Alamo Group management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

TEUM

Pareteum

$2.48

-0.1 (-3.88%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
Pareteum management to meet with Maxim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 17

    Jul

  • 12

    Sep

MGPI

MGP Ingredients

$61.75

-4.45 (-6.72%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
MGP Ingredients management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

CSV

Carriage Services

$18.98

-0.15 (-0.78%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
Carriage Services management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

HMSY

HMS Holdings

$30.79

-1.07 (-3.36%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
HMS Holdings management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

PATK

Patrick Industries

$46.36

-1.73 (-3.60%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
Patrick Industries management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

ETSY

Etsy

$63.90

-1.84 (-2.80%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
Etsy management to meet with BTIG »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

NEE

NextEra Energy

$208.20

0.51 (0.25%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
NextEra Energy management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

INWK

InnerWorkings

$3.87

-0.3 (-7.19%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
InnerWorkings management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

INO

Inovio

$2.42

-0.205 (-7.82%)

04:55
06/25/19
06/25
04:55
06/25/19
04:55
Conference/Events
Inovio management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.